Dissecting Structural Requirements of Leucinostatin A Derivatives for Antiprotozoal Activity and Mammalian Toxicity
Journal of Medicinal Chemistry · 27.02.2025 · 68 (4) · 4237-4258
DOI: 10.1021/acs.jmedchem.4c01989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 14.02.2025. Verfasst von Lukas Rimle und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Freiestrasse 3, 3012 Bern, Switzerland. Hauptthemen laut MEDLINE: Antiprotozoal Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung, Innosuisse - Schweizerische Agentur f?r Innovationsf?rderung, Research Foundation of University of Bern.
Abstract (Originalsprache)
Lefleuganan, a clinical stage drug candidate for the treatment of cutaneous leishmaniasis, is a synthetic nonapeptide inspired by the natural antimicrobial peptide leucinostatin A, exhibiting excellent antiprotozoal activity in the low nM range. Lefleuganan shows strongly reduced acute toxicity, making it amenable for clinical use. Here, using a broad set of in vivo and in vitro measurements using purified enzymes, we find that leucinostatin A, but not lefleuganan, specifically targets the mitochondrial ATP synthase, inhibiting ATP synthesis by the human, bovine, and yeast enzyme in the nanomolar range. In a structure-activity relationship study covering the chemical space between the two compounds, hydroxyleucine at position 7 in leucinostatin A is identified as the key responsible moiety for specific ATP synthase inhibition and systemic toxicity. Our data suggest that efficient antiprotozoal activity of these class of compounds is mediated by efficient energetic uncoupling of negatively charged membranes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Freiestrasse 3, 3012 Bern, Switzerland.
- Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland.
- Institute of Chemistry and Biotechnology, Competence Center for Drug Discovery, Zurich University of Applied Sciences (ZHAW), Einsiedlerstrasse 31, 8820 Wädenswil, Switzerland.
- Institute of Clinical Chemistry, Inselspital, University Hospital Bern, 3010 Bern, Switzerland.
- Swiss Tropical and Public Health Institute, Kreuzstrasse 2, 4123 Allschwil, Switzerland.
- University of Basel, Petersplatz 1, 4002 Basel, Switzerland.
ORCID-Profile: Pascal Mäser, Christoph von Ballmoos
Förderung
- Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung
- Innosuisse - Schweizerische Agentur f?r Innovationsf?rderung
- Research Foundation of University of Bern
Zitieren
APA
Rimle, L., Pliatsika, D., Arnold, N., Kurth, S., Kaiser, M., Mäser, P., Kemmler, M., Adams, M., Riedl, R., & von Ballmoos, C. (2025). Dissecting Structural Requirements of Leucinostatin A Derivatives for Antiprotozoal Activity and Mammalian Toxicity. Journal of Medicinal Chemistry, 68(4), 4237-4258. https://doi.org/10.1021/acs.jmedchem.4c01989
Vancouver
Rimle L, Pliatsika D, Arnold N, Kurth S, Kaiser M, Mäser P, et al. Dissecting Structural Requirements of Leucinostatin A Derivatives for Antiprotozoal Activity and Mammalian Toxicity. Journal of Medicinal Chemistry. 2025;68(4):4237-4258. doi:10.1021/acs.jmedchem.4c01989
BibTeX
@article{Rimle2025,
author = {Rimle, Lukas and Pliatsika, Dimanthi and Arnold, Noëlle and Kurth, Sandra and Kaiser, Marcel and Mäser, Pascal and Kemmler, Michael and Adams, Michael and Riedl, Rainer and von Ballmoos, Christoph},
title = {Dissecting Structural Requirements of Leucinostatin A Derivatives for Antiprotozoal Activity and Mammalian Toxicity},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {4},
pages = {4237--4258},
doi = {10.1021/acs.jmedchem.4c01989}
}
EUVIMED